Physician profile
Joseph A Smith
NPI 1366524761
$4,033.69
in general payments reported to CMS, 2019-2025
31 companies · $854 in 2025
The $854 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $798 · 2021: $431 · 2022: $105 · 2023: $600 · 2024: $686 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $749.81 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $523.70 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $449.25 | 2020-2025 | Arexvy, Shingrix |
| Lilly USA, LLC | $284.81 | 2019-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.77 | 2019-2023 | Jardiance, Synjardy |
| Pfizer INC. | $243.86 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $232.42 | 2024-2025 | |
| Amarin Pharma, INC. | $160.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $156.99 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Abbvie INC. | $151.24 | 2021-2022 | |
| Allergan, INC. | $129.52 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.57 | 2022-2025 | |
| Inspire Medical Systems, INC. | $89.24 | 2024-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $77.99 | 2019 | |
| Exact Sciences Corporation | $48.40 | 2024-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $46.42 | 2023-2024 | Freestyle Libre 3 |
| Amgen INC. | $43.29 | 2019-2023 | Repatha, Otezla |
| Coloplast Corp | $31.97 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $28.57 | 2019 | |
| Daiichi Sankyo INC. | $28.40 | 2019-2020 | |
| Eisai INC. | $28.14 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $23.95 | 2020 | |
| Boston Scientific Corporation | $20.19 | 2025 | Ams 700 |
| Ibsa Pharma INC. | $18.43 | 2025 | Flector, Licart, Tirosint |
| Esperion Therapeutics, INC. | $15.40 | 2023 | Nexletol |
| Genentech USA, INC. | $15.00 | 2019 | |
| Currax Pharmaceuticals LLC | $13.54 | 2020 | |
| Sanofi Pasteur INC. | $13.50 | 2019 | |
| Astellas Pharma US INC | $12.03 | 2020 | |
| Vivus LLC | $11.29 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.